Daniels Lydia, Barker Sally, Chang Yoon-Seok, Chikovani Tinatin, DunnGalvin Audrey, Gerdts Jennifer D, Gerth Van Wijk Roy, Gibbs Trevor, Villarreal-Gonzalez Rosalaura V, Guzman-Avilan Rosa I, Hanna Heather, Hossny Elham, Kolotilina Anastasia, Ortega Martell José Antonio, Pacharn Punchama, de Lira Quezada Cindy E, Sibanda Elopy, Stukus David, Tham Elizabeth Huiwen, Venter Carina, Gonzalez-Diaz Sandra N, Levin Michael E, Martin Bryan, Munblit Daniel, Warner John O
Faculty of Medicine, Imperial College London, London, UK.
Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea.
World Allergy Organ J. 2021 Sep 25;14(10):100584. doi: 10.1016/j.waojou.2021.100584. eCollection 2021 Oct.
There is a wide time gap between the publication of evidence and the application of new knowledge into routine clinical practice. The consequence is sub-optimal outcomes, particularly concerning for long-term relapsing/remitting conditions such as allergic diseases. In response, there has been a proliferation of published guidelines which systematically review evidence for the gold-standard management of most allergic disorders. However, this has not necessarily been followed by improved outcomes, partly due to a lack of coordination across the patient pathway. This has become known as the "second translational gap". A proposed solution is the development and implementation of integrated care pathways (ICPs) to optimize patient outcomes, with the notion that evidence-based medicine requires evidence-based implementation. ICP implementation is shown to improve short-term outcomes for acute conditions and routine surgery, including reduced length of hospital stay, improved documentation and improved patient safety. However, this improvement is not reflected in patient experience or patient-centered functional outcomes. The implementation of life-long, cost-effective interventions within comprehensive pathways requires a deep appreciation for complexity within allergy care. We promote an evidence-based methodology for the implementation of ICPs for allergic disorders in which all stakeholders in allergy care are positioned equally and encouraged to contribute, particularly patients and their caregivers. This evidence-based process commences with scoping the unmet needs, followed by stakeholder mapping. All stakeholders are invited to meetings to develop a common vision and mission through the generation of action/effect diagrams which helps build concordance across the agencies. Dividing the interventions into achievable steps and reviewing with plan/do/study/act cycles will gradually modify the pathway to achieve the best outcomes. While the management guidelines provide the core knowledge, the key component of implementation involves education, training, and support of all healthcare professionals (HCPs), patients and their caregivers. The pathways should define the level of competence required for each clinical task. It may be useful to leave the setting of care delivery or the specific HCP involved undefined to account for variable patterns of health service delivery as well as local socioeconomic, ethnic, environmental, and political imperatives. In all cases, where competence is exceeded, it is necessary to refer to the next stage in the pathway. The success and sustainability of ICPs would ideally be judged by patient experience, health outcomes, and health economics. We provide examples of successful programs, most notably from Finland, but recommend that further research is required in diverse settings to optimize outcomes worldwide.
证据发表与将新知识应用于日常临床实践之间存在很大的时间间隔。其后果是治疗效果欠佳,对于诸如过敏性疾病等长期复发/缓解性病症而言尤其如此。作为应对措施,已发表的指南大量涌现,这些指南系统地回顾了大多数过敏性疾病金标准治疗的证据。然而,这并不一定会带来更好的治疗效果,部分原因是患者就医流程缺乏协调。这就是所谓的“第二个转化差距”。一个提议的解决方案是开发并实施综合护理路径(ICP)以优化患者治疗效果,其理念是循证医学需要循证实施。ICP的实施已被证明能改善急性病症和常规手术的短期治疗效果,包括缩短住院时间、改善病历记录以及提高患者安全性。然而,这种改善并未体现在患者体验或以患者为中心的功能结局上。在综合护理路径中实施长期且具成本效益的干预措施需要深刻理解过敏症护理的复杂性。我们倡导一种基于证据的方法来实施针对过敏性疾病的ICP,在这种方法中,过敏症护理的所有利益相关者处于平等地位并受到鼓励做出贡献,尤其是患者及其护理人员。这个基于证据的过程始于确定未满足的需求,接着是绘制利益相关者图谱。邀请所有利益相关者参加会议,通过生成行动/效果图来形成共同的愿景和使命,这有助于在各机构间达成共识。将干预措施分解为可实现的步骤,并通过计划/执行/研究/行动循环进行审查,将逐步调整护理路径以实现最佳治疗效果。虽然管理指南提供了核心知识,但实施的关键要素涉及对所有医疗保健专业人员(HCP)、患者及其护理人员的教育、培训和支持。护理路径应明确每项临床任务所需的能力水平。不明确护理提供的场所或涉及的具体HCP可能会有所帮助,以便考虑到卫生服务提供的不同模式以及当地的社会经济、种族、环境和政治因素。在所有情况下,如果能力超出要求,就有必要参考护理路径的下一阶段。ICP的成功与可持续性理想情况下应由患者体验、健康结局和卫生经济学来评判。我们提供了成功项目的实例,最显著的是来自芬兰的例子,但建议在不同环境中进行进一步研究以在全球范围内优化治疗效果。